CLAIMS

WHAT IS CLAIMED IS:

1. A compound of Formula (I), or a pharmaceutically acceptable salt, or stereoisomer thereof:



Formula (I),

wherein:

R^1 is monocyclic heterocycloalkyl optionally and independently substituted with one or more R^{1a};

each R^{1a} is independently halogen, -CN, -NO_2, -OH, -OR^a, -$OC(=O)R^a$, -$OC(=O)OR^b$, -$OC(=O)NR^cR^d$, -SH, -SR^a, -$S(=O)R^a$, -$S(=O)_2R^a$, -$S(=O)_2NR^cR^d$, -NR^cR^d, -$NR^bC(=O)NR^cR^d$, -$NR^bC(=O)R^a$, -$NR^bC(=O)OR^b$, -$NR^bS(=O)_2R^a$, -$C(=O)R^a$, -$C(=O)OR^b$, -$C(=O)NR^cR^d$, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

or two R^{1a} on the same atom are taken together to form an oxo;

X is N or CR^2;

R^2 is hydrogen, fluoro, chloro, bromo, -CN, -NO_2, -OH, -OR^a, -$C(=O)R^a$, -$C(=O)OR^b$, -$C(=O)NR^cR^d$, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, or C_1-C_6heteroalkyl;

R^3 is hydrogen, halogen, -CN, -NO_2, -OH, -OR^a, -$C(=O)R^a$, -$C(=O)OR^b$, -$C(=O)NR^cR^d$, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, or C_1-C_6heteroalkyl;

R^4 is hydrogen, halogen, -CN, -NO_2, -OH, -OR^a, -$C(=O)R^a$, -$C(=O)OR^b$, -$C(=O)NR^cR^d$, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, or C_1-C_6heteroalkyl;

R^5 is hydrogen, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, or C_1-C_6heteroalkyl;

Y is -O-, -S-, or -NR^6-;

R^6 is hydrogen, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, or C_1-C_6heteroalkyl;

L is -$(CR^7R^8)_p$-;

each R^7 and R^8 are independently hydrogen, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, or C_1-C_6heteroalkyl;

or R^7 and R^8 on the same carbon are taken together to form a cycloalkyl or heterocycloalkyl; each optionally substituted with one or more R^{7a};

each R^{7a} is independently halogen, -CN, -NO_2, -OH, -OR^a, -NR^cR^d, -$C(=O)R^a$, -$C(=O)OR^b$, -$C(=O)NR^cR^d$, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, or C_1-C_6heteroalkyl;

p is 0-4;

Ring A is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

each R^9 is independently halogen, -CN, $-NO_2$, -OH, $-OR^a$, $-OC(=O)R^a$, $-OC(=O)OR^b$, $-OC(=O)NR^cR^d$, -SH, $-SR^a$, $-S(=O)R^a$, $-S(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, $-NR^bS(=O)_2R^a$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R^{9a};

or two R^9 on the same atom are taken together to form an oxo;

each R^{9a} is independently halogen, -CN, $-NO_2$, -OH, $-OR^a$, $-OC(=O)R^a$, $-OC(=O)OR^b$, $-OC(=O)NR^cR^d$, -SH, $-SR^a$, $-S(=O)R^a$, $-S(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, $-NR^bS(=O)_2R^a$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

or two R^{9a} on the same atom are taken together to form an oxo;

n is 0-4;

each R^a is independently C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1-C_6alkylene(cycloalkyl), C_1-C_6alkylene(heterocycloalkyl), C_1-C_6alkylene(aryl), or C_1-C_6alkylene(heteroaryl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R;

each R^b is independently hydrogen, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1-C_6alkylene(cycloalkyl), C_1-C_6alkylene(heterocycloalkyl), C_1-C_6alkylene(aryl), or C_1-C_6alkylene(heteroaryl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R;

each R^c and R^d are independently hydrogen, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1-C_6alkylene(cycloalkyl), C_1-C_6alkylene(heterocycloalkyl), C_1-C_6alkylene(aryl), or C_1-C_6alkylene(heteroaryl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R;

or R^c and R^d are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R; and

each R is independently halogen, -CN, -OH, $-OC_1$-C_6alkyl, $-S(=O)C_1$-C_6alkyl, $-S(=O)_2C_1$-C_6alkyl, $-S(=O)_2NH_2$, $-S(=O)_2NHC_1$-C_6alkyl, $-S(=O)_2N(C_1$-C_6alkyl$)_2$, $-NH_2$, $-NHC_1$-C_6alkyl, $-N(C_1$-C_6alkyl$)_2$, $-NHC(=O)OC_1$-C_6alkyl, $-C(=O)C_1$-C_6alkyl, -C(=O)OH, $-C(=O)OC_1$-C_6alkyl, $-C(=O)NH_2$, $-C(=O)N(C_1$-C_6alkyl$)_2$, $-C(=O)NHC_1$-C_6alkyl, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, or C_1-C_6heteroalkyl; or

two R on the same atom are taken together to form an oxo.

2. The compound of claim 1, or a pharmaceutically acceptable salt, or stereoisomer thereof, wherein X is CR^2 and R^2 is hydrogen, fluoro, or C_1-C_6alkyl.
3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt, or stereoisomer thereof, wherein R^3 is hydrogen, halogen, C_1-C_6alkyl, or C_1-C_6haloalkyl and R^4 is hydrogen, halogen, C_1-C_6alkyl, or C_1-C_6haloalkyl.
4. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt, or stereoisomer thereof, wherein R^3 is hydrogen and R^4 is hydrogen.
5. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt, or stereoisomer thereof, wherein R^5 is hydrogen or C_1-C_6alkyl.
6. The compound of claim 5, or a pharmaceutically acceptable salt, or stereoisomer thereof, wherein R^5 is hydrogen.
7. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt, or stereoisomer thereof, wherein Y is $-NR^6-$ and R^6 is hydrogen or C_1-C_6alkyl.
8. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt, or stereoisomer thereof, wherein p is 1 and R^7 and R^8 are independently hydrogen or C_1-C_6alkyl.
9. The compound of claim 8, or a pharmaceutically acceptable salt, or stereoisomer thereof, wherein each R^7 and R^8 are hydrogen.
10. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt, or stereoisomer thereof, wherein Ring A is phenyl or 5- or 6-membered heteroaryl.
11. The compound of any one of claims 1-10, or a pharmaceutically acceptable salt, or stereoisomer thereof, wherein Ring A is 6-membered heteroaryl.
12. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt, or stereoisomer thereof, wherein n is 1 or 2 and each R^9 is independently halogen, -CN, -OH, $-OR^a$, $-NR^cR^d$, $-C(=O)OR^b$, C_1-C_6alkyl, or C_1-C_6haloalkyl.
13. The compound of claim 12, or a pharmaceutically acceptable salt, or stereoisomer thereof, wherein each R^9 is independently halogen or -CN.
14. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt, or stereoisomer thereof, wherein R^1 is 5-7 membered monocyclic heterocycloalkyl optionally and independently substituted with 1 or 2 R^{1a}, and wherein the monocyclic heterocycloalkyl contains 1-3 ring nitrogen atoms.
15. The compound of any one of claims 1-14, or a pharmaceutically acceptable salt, or stereoisomer thereof, wherein each R^{1a} is independently halogen, -OH, $-OR^a$, $-NR^bC(=O)R^a$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6heteroalkyl, or cycloalkyl; or two R^{1a} on the same atom are taken together to form an oxo.
16. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt, or stereoisomer thereof, wherein each R^{1a} is independently C_1-C_6alkyl, C_1-C_6haloalkyl, or $-C(=O)OR^b$.

17. The compound of claim 1, or a pharmaceutically acceptable salt, or stereoisomer thereof; which is a compound selected from the following compounds, or a pharmaceutically acceptable salt, or stereoisomer thereof:


,


,


,


,


,


,


,


,


,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,


OH
O
N
H
N
N
N
N
CN
O
O
,

OH
O
N
H
N
N
N
N
CN
O
O
O
,

OH
O
N
H
N
N
N
N
CN
O
O
,

OH
O
N
H
N
N
N
N
CN
O
O
,

OH
O
N
H
N
N
N
N
CN
O
O
,

OH
O
N
H
N
N
N
N
CN
O
O
,

OH
O
N
H
N
N
N
N
CN
O
O
Boc
,


,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,



,



,



,



,



.

18. The compound of claim 1, or a pharmaceutically acceptable salt, or stereoisomer thereof, which is the following compound, or a pharmaceutically acceptable salt, or stereoisomer thereof:



.

19. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of claims 1-18, or a pharmaceutically acceptable salt, or stereoisomer thereof, and a pharmaceutically acceptable excipient.

20. Use of a compound of any one of claims 1-18, or a pharmaceutically acceptable salt, or stereoisomer thereof, in the manufacture of a medicament for treating a disease or disorder in a subject, wherein the disease or disorder is inflammatory bowel disease (IBD).

21. A compound of any one of claims 1-18, or a pharmaceutically acceptable salt, or stereoisomer thereof, for use as a medicament.